Drug Profile
Research programme: mitogen activated protein kinase inhibitors - Kura Oncology
Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Araxes Pharma
- Developer Araxes Pharma; Kura Oncology
- Class Small molecules
- Mechanism of Action Mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours